<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38714218</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7492</ISSN><JournalIssue CitedMedium="Internet"><Volume>345</Volume><PubDate><Year>2024</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Virus research</Title><ISOAbbreviation>Virus Res</ISOAbbreviation></Journal><ArticleTitle>Doxycycline inhibits neurotropic enterovirus proliferation in vitro.</ArticleTitle><Pagination><StartPage>199388</StartPage><MedlinePgn>199388</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">199388</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virusres.2024.199388</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0168-1702(24)00081-9</ELocationID><Abstract><AbstractText>Human enteroviruses (EVs) represent a global public health concern due to their association with a range of serious pediatric illnesses. Despite the high morbidity and mortality exerted by EVs, no broad-spectrum antivirals are currently available. Herein, we presented evidence that doxycycline can inhibit in vitro replication of various neurotropic EVs, including enterovirus A71 (EV-A71), enterovirus D68 (EV-D68), and coxsackievirus (CV)-A6, in a dose-dependent manner. Further investigations indicated that the drug primarily acted at the post-entry stage of virus infection in vitro, with inhibitory effects reaching up to 89 % for EV-A71 when administered two hours post-infection. These findings provide valuable insights for the development of antiviral drugs against EV infections.</AbstractText><CopyrightInformation>Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chi</LastName><ForeName>Fengyu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Public Health, Shandong First Medical University &amp; Shandong Academy of Medical Sciences, Ji'nan 250117, China; Key Laboratory of Emerging Infectious Diseases in Universities of Shandong, Shandong First Medical University &amp; Shandong Academy of Medical Sciences, Taian 271000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xinzhuo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Public Health, Shandong First Medical University &amp; Shandong Academy of Medical Sciences, Ji'nan 250117, China; Key Laboratory of Emerging Infectious Diseases in Universities of Shandong, Shandong First Medical University &amp; Shandong Academy of Medical Sciences, Taian 271000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Clinical and Basic Medical Sciences, Shandong First Medical University &amp; Shandong Academy of Medical Sciences, Ji'nan 250117, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Moujian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhenjie</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>School of Clinical and Basic Medical Sciences, Shandong First Medical University &amp; Shandong Academy of Medical Sciences, Ji'nan 250117, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Clinical and Basic Medical Sciences, Shandong First Medical University &amp; Shandong Academy of Medical Sciences, Ji'nan 250117, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carr</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>National Virus Reference Laboratory, School of Medicine, University College Dublin, D04 E1W1, Ireland; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Public Health, Shandong First Medical University &amp; Shandong Academy of Medical Sciences, Ji'nan 250117, China; Key Laboratory of Emerging Infectious Diseases in Universities of Shandong, Shandong First Medical University &amp; Shandong Academy of Medical Sciences, Taian 271000, China. Electronic address: liyuming@sdfmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Weifeng</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Shanghai Institute of Virology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: shiwf@ioz.ac.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Virus Res</MedlineTA><NlmUniqueID>8410979</NlmUniqueID><ISSNLinking>0168-1702</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>N12000U13O</RegistryNumber><NameOfSubstance UI="D004318">Doxycycline</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004318" MajorTopicYN="Y">Doxycycline</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030016" MajorTopicYN="N">Enterovirus D, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral</Keyword><Keyword MajorTopicYN="N">Doxycycline</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Picornavirus</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>28</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>8</Day><Hour>2</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>7</Day><Hour>19</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38714218</ArticleId><ArticleId IdType="pmc">PMC11127601</ArticleId><ArticleId IdType="doi">10.1016/j.virusres.2024.199388</ArticleId><ArticleId IdType="pii">S0168-1702(24)00081-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andino R., Kirkegaard K., Macadam A., Racaniello V.R., Rosenfeld A.B. The picornaviridae family: knowledge gaps, animal models, countermeasures, and prototype pathogens. J. Infect. Dis. 2023;228(Suppl 6):S427–S445.</Citation><ArticleIdList><ArticleId IdType="pubmed">37849401</ArticleId></ArticleIdList></Reference><Reference><Citation>Balducci C., Forloni G. Doxycycline for Alzheimer’s disease: fighting β-amyloid oligomers and neuroinflammation. Front. Pharmacol. 2019;3(10):738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6616274</ArticleId><ArticleId IdType="pubmed">31333460</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L., Gao F., Mao Q., Sun S., Wu X., Liu S., Yang X., Liang Z. Hand, foot, and mouth disease associated with coxsackievirus A10: more serious than it seems. Expert Rev. Anti-Infect. Ther. 2019;17(4):233–242.</Citation><ArticleIdList><ArticleId IdType="pubmed">30793637</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnetblanc J.M. [Doxycycline] Ann. Dermatol. Venereol. 2002;129(6–7):874–882.</Citation><ArticleIdList><ArticleId IdType="pubmed">12218915</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubba L., Broberg E.K., Jasir A., Simmonds P., Harvala H. Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study. Lancet Infect. Dis. 2020;20(3):350–361.</Citation><ArticleIdList><ArticleId IdType="pubmed">31870905</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong Teoh T., S J.A.H., Abdulrahman A.Y., Rothan H.A. Doxycycline interferes with Zika virus serine protease and inhibits virus replication in human skin fibroblasts. Molecules. 2021;26(14)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8306286</ArticleId><ArticleId IdType="pubmed">34299596</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang Y.Y., Huang Y.C. Enteroviral infection in neonates. J. Microbiol. Immunol. Infect. 2019;52(6):851–857.</Citation><ArticleIdList><ArticleId IdType="pubmed">31607572</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemens D.L., Duryee M.J., Hall J.H., Thiele G.M., Mikuls T.R., Klassen L.W., Zimmerman M.C., Anderson D.R. Relevance of the antioxidant properties of methotrexate and doxycycline to their treatment of cardiovascular disease. Pharmacol. Ther. 2020;205</Citation><ArticleIdList><ArticleId IdType="pubmed">31626869</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Caprio R., Lembo S., Di Costanzo L., Balato A., Monfrecola G. Anti-inflammatory properties of low and high doxycycline doses: an in vitro study. Mediat. Inflamm. 2015;2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4421036</ArticleId><ArticleId IdType="pubmed">25977597</ArticleId></ArticleIdList></Reference><Reference><Citation>Feitosa R.C., Ishikawa E.S.A., Silva M., Silva-Júnior A.A.D., Oliveira-Nascimento L. Five decades of doxycycline: does nanotechnology improve its properties? Int. J. Pharm. 2022;25(618)</Citation><ArticleIdList><ArticleId IdType="pubmed">35283220</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost J., Rudy M.J., Leser J.S., Tan H., Hu Y., Wang J., Clarke P., Tyler K.L. Telaprevir treatment reduces paralysis in a mouse model of enterovirus D68 acute flaccid myelitis. J. Virol. 2023;97(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10231134</ArticleId><ArticleId IdType="pubmed">37154751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi K., Ghasemi K. A Brief look at antitumor effects of doxycycline in the treatment of colorectal cancer and combination therapies. Eur. J. Pharmacol. 2022;916</Citation><ArticleIdList><ArticleId IdType="pubmed">34973952</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Musharrafieh R., Zheng M., Wang J. Enterovirus D68 antivirals: past, present, and future. ACS Infect. Dis. 2020;6(7):1572–1586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055446</ArticleId><ArticleId IdType="pubmed">32352280</ArticleId></ArticleIdList></Reference><Reference><Citation>ICTV. "Family: picornaviridae; genus: enterovirus." 2024 from https://ictv.global/report/chapter/picornaviridae/picornaviridae/enterovirus.</Citation></Reference><Reference><Citation>Isaacs S.R., Roy A., Dance B., Ward E.J., Foskett D.B., Maxwell A.J., Rawlinson W.D., Kim K.W., Craig M.E. Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins. Lancet Diabetes Endocrinol. 2023;11(8):578–592.</Citation><ArticleIdList><ArticleId IdType="pubmed">37390839</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantele A., Mero S., Lääveri T. Doxycycline as an antimalarial: impact on travellers' diarrhoea and doxycycline resistance among various stool bacteria–prospective study and literature review. Travel Med. Infect. Dis. 2022;49</Citation><ArticleIdList><ArticleId IdType="pubmed">35872253</ArticleId></ArticleIdList></Reference><Reference><Citation>Krug P.W., Wang L., Shi W., Kong W.P., Moss D.L., Yang E.S., Fisher B.E., Morabito K.M., Mascola J.R., Kanekiyo M., Graham B.S., Ruckwardt T.J. EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination. Sci. Adv. 2023;9(20):eadg6076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10191429</ArticleId><ArticleId IdType="pubmed">37196074</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J.Y., Kung Y.A., Shih S.R. Antivirals and vaccines for Enterovirus A71. J. Biomed. Sci. 2019;26(1):65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6720414</ArticleId><ArticleId IdType="pubmed">31481071</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd R.E., Tamhankar M., Lernmark Å. Enteroviruses and type 1 diabetes: multiple mechanisms and factors? Annu. Rev. Med. 2022;73:483–499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9242008</ArticleId><ArticleId IdType="pubmed">34794324</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchetti J., Fracasso C., Balducci C., Passoni A., Forloni G., Salmona M., Gobbi M. Plasma and brain concentrations of doxycycline after single and repeated doses in wild-type and APP23 mice. J. Pharmacol. Exp. Ther. 2019;368(1):32–40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30396916</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothan H.A., Mohamed Z., Paydar M., Rahman N.A., Yusof R. Inhibitory effect of doxycycline against dengue virus replication in vitro. Arch. Virol. 2014;159(4):711–718.</Citation><ArticleIdList><ArticleId IdType="pubmed">24142271</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Chen P., Bai Y., Xu X., Liu Y. Seroprevalence of coxsackievirus A6 and enterovirus A71 infection in humans: a systematic review and meta-analysis. Arch. Virol. 2023;168(2):37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9825098</ArticleId><ArticleId IdType="pubmed">36609748</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Hu Y., Zheng M. Enterovirus A71 antivirals: past, present, and future. Acta Pharm. Sin. B. 2022;12(4):1542–1566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9279511</ArticleId><ArticleId IdType="pubmed">35847514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N., Tian X., Chen Y., Tan H.Q., Xie P.J., Chen S.J., Fu Y.C., Chen Y.X., Xu W.C., Wei C.J. Low dose doxycycline decreases systemic inflammation and improves glycemic control, lipid profiles, and islet morphology and function in db/db mice. Sci. Rep. 2017;7(1):14707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5666019</ArticleId><ArticleId IdType="pubmed">29089617</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z.C., Wang X., Wei J.C., Li B.B., Shao D.H., Li Y.M., Liu K., Shi Y.Y., Zhou B., Qiu Y.F., Ma Z.Y. Antiviral activity of doxycycline against vesicular stomatitis virus in vitro. FEMS Microbiol. Lett. 2015;362(22)</Citation><ArticleIdList><ArticleId IdType="pubmed">26459887</ArticleId></ArticleIdList></Reference><Reference><Citation>Zell R. Picornaviridae-the ever-growing virus family. Arch. Virol. 2018;163(2):299–317.</Citation><ArticleIdList><ArticleId IdType="pubmed">29058149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Zhang Y., Li H., Liu L. Hand-foot-and-mouth disease-associated enterovirus and the development of multivalent HFMD vaccines. Int. J. Mol. Sci. 2022;24(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9820767</ArticleId><ArticleId IdType="pubmed">36613612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo J., Quinn K.K., Kye S., Cooper P., Damoiseaux R., Krogstad P. Fluoxetine is a potent inhibitor of coxsackievirus replication. Antimicrob. Agents Chemother. 2012;56(9):4838–4844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3421851</ArticleId><ArticleId IdType="pubmed">22751539</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>